Journal
Breast cancer research
Publication Date
10-16-2019
Volume
21
Issue
1
First Page
110
Document Type
Open Access Publication
DOI
10.1186/s13058-019-1190-4
Rights and Permissions
Park, S., Han, Y., Liu, Y. et al. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30. Breast Cancer Res 21, 110 (2019). https://doi.org/10.1186/s13058-019-1190-4 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Recommended Citation
Park, Seho; Han, Yunan; Liu, Ying; Toriola, Adetunji T; Peterson, Lindsay L; Colditz, Graham A; Kim, Seung Il; Cho, Young Up; Park, Byeong-Woo; and Park, Yikyung, "Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30." Breast cancer research. 21, 1. 110 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9050
Additional File 1. Figure with CONSORT diagram.
13058_2019_1190_MOESM2_ESM.docx (80 kB)
Additional File 2. Figure with distribution of the 21-gene RS.
13058_2019_1190_MOESM3_ESM.docx (14 kB)
Additional File 3. Table with multivariate analysis for risks of breast cancer-specific and overall mortality by the 21-gene RS in sensitivity analyses that included breast cancer with HER2-positive, borderline, and unknown status in 2010–2015
13058_2019_1190_MOESM4_ESM.docx (18 kB)
Additional File 4. Table with patients’ characteristics by chemotherapy use in patients aged ≤70 years old with the recurrence score (RS) 26–30.
